cyrilzakka/clinical-trials huggingface dataset:
Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison

Medications used to relax the muscles are used during surgery. The amount of muscle relaxation can monitored with devices that stimulate a specific nerve and evaluate the muscle response. The response to, and recovery from, medications that relax the muscles are best described for a nerve in the arm called the ulnar nerve. The investigators believe that other nerves in the arm, such as the median nerve, could be used to monitor the amount of muscle relaxation. The purpose of this study is to compare the muscle response at two different nerve sites after giving medications to relax the muscles.

This study is going to measure the depth of muscle relaxation during surgery at two different sites. The muscle response to stimulation of the ulnar nerve (located in the arm) will be compared to the muscle response to stimulation of the median nerve (also located in the arm).

This is a single-center prospective, randomized controlled trial comparing ulnar versus median nerve electromyography transmission.

Neuromuscular blockade is used to provide muscle relaxation during surgery. The depth of neuromuscular blockade can be monitored with nerve stimulation or electromyography. The response to and recovery from non-depolarizing neuromuscular blockade is best described for the ulnar nerve. The investigators postulate that the median nerve may provide comparable information about the response non-depolarizing neuromuscular blockade. Electromyography electrodes will be positioned to stimulate the ulnar nerve in one arm and the median nerve in the other arm. The response to, and recovery from, non-depolarizing neuromuscular blockade will be compared between the ulnar and median nerve.

The location of median nerve monitoring will be randomized to the dominant or non-dominant hand.

The randomized arm will have electrodes positioned to stimulate the median nerve and the other arm will have electrodes positioned to stimulate the ulnar nerve (standard site for monitoring neuromuscular transmission during anesthesia).

The purpose of the study is to compare the response to, and recovery from, non-depolarizing neuromuscular blockade between the ulnar and median nerves.

Eligibility Criteria:
Inclusion Criteria:

* Adults 18 - 75 years of age who are able to provide consent
* Scheduled for elective surgery requiring muscle relaxation, in a supine position under general anesthesia, with an anticipated duration of at least 1.5 hours

Exclusion Criteria:

* Contraindication to rocuronium use
* Comorbidities that may prolong the duration of neuromuscular blockade or alter pharmacodynamics and/or pharmacokinetics, such as:
* Neuromuscular disease
* Expected or known difficult airway
* Rocuronium allergy
* BMI \< 18.5 or \> 40
* History of adhesive allergy
* Upper extremity weakness, limb deformity, or absence of all or part of an upper limb
* Patients undergoing surgical procedures requiring cardiopulmonary bypass
A Study of LY3462817 in Participants With Rheumatoid Arthritis

The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).


Eligibility Criteria:
Inclusion Criteria:

* Have a diagnosis of adult onset RA as defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for at least 3 months prior to screening
* Have moderately to severely active RA defined by the presence of ≥6 swollen joints (based on 66 joint count) and ≥6 tender joints (based on 68 joint count) at screening and baseline. The distal interphalangeal joint should be evaluated but not included in the total count to determine eligibility
* Have at least 1 of the following:

  * positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at screening, OR
  * previous radiographs documenting bony erosions in hands or feet consistent with RA
* Have C-reactive protein (CRP) \>1.2 times upper limit of normal (ULN) per the central laboratory at screening
* Demonstrated an inadequate response to, or loss of response or intolerance to:

  * at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) treatment OR
  * at least 1 biologic DMARD/tsDMARD treatment

Exclusion Criteria:

* Class IV RA according to ACR revised response criteria
* Have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of:

  * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or
  * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline
* Have presence of confirmed cervical dysplasia
* Have had various types of infection within 3 months of screening or develops any of these infections before the randomization visit.
* Have any of the following:

  * Human immunodeficiency virus (HIV) infection
  * Current infection with hepatitis B virus (HBV) (i.e., positive for hepatitis B surface antigen and/or polymerase chain reaction (PCR) positive for HBV DNA
  * Current infection with hepatitis C virus (HCV) (i.e., positive for HCV RNA)
  * Active tuberculosis (TB)
* Have failed more than 2 biologic DMARDs (bDMARDs) or tsDMARDs (e.g. excluded if have received 2 bDMARDs and 1 tsDMARD)
Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy

The purpose of this study is to define phenotypic variations in atrophic Age-Related Macular Degeneration (AMD) and to identify predictive factors for disease progression based on fundus autofluorescence imaging.

Age-related macular degeneration (AMD) is the leading cause of legal blindness in the industrialized world beyond 50 years of age. Ageing changes of the retinal pigment epithelium (RPE) play a key role in the pathogenesis of the disease. In postmitotic RPE cells autofluorescent lipofuscin granules accumulate with age in the lysosomal compartment mainly as a byproduct of constant phagocytosis of membranous disks shed from photoreceptor outer segments. With the advent of confocal scanning laser ophthalmoscopy fundus autofluorescence mediated by RPE-lipofuscin accumulation can be visualized in vivo: We plan to identify fundus autofluorescence changes as predictive factors for the development of late stage manifestations and their variation over time. Furthermore, we plan to determine the effect of increased focal accumulations of autofluorescent material on retinal sensitivity using fundus perimetry. Examination of human donor eyes with AMD will allow for correlation of fundus autofluorescence alterations in vivo and in vitro. These investigations will be performed not only to better understand the role of lipofuscin accumulation in AMD but also to manipulate these mechanisms for both experimental and therapeutic ends.

Eligibility Criteria:
Inclusion Criteria:

* Must be considered reliable, willing and able to give informed consent.
* Age \>50 years (male or female)
* Must have age-related macular degeneration in at least one eye
* Clear media to allow imaging

Exclusion Criteria:

* any history of retinal surgery, including laser treatment, photodynamic therapy, radiation or intravitreal injections
* history of retinal vascular occlusions
* any concurrent intraocular condition that, in the opinion of the investigator, could exclude the patient from the medical or ethical point of view
Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.

This study aims to compare the efficacy of topical 5-fluorouracil versus topical latanoprost after skin microneedling in the induction of skin repigmentation in localized stable vitiligo patients.

Vitiligo is an acquired pigmentary disorder characterized by depigmented macules and patches secondary to the loss of functional melanocytes. It is a chronic disease that affects between 0.1% and 2% of the general population, affecting both sexes and all races.

Theories regarding loss of melanocytes are based on autoimmune, cytotoxic, oxidant-antioxidant and neural mechanisms.

Therapeutic strategies for vitiligo include nonsurgical and surgical methods. Nonsurgical options include topical corticosteroids and topical calcineurin inhibitors. Phototherapy as psoralen and ultraviolet A (PUVA) and narrow-band ultraviolet B (NB-UVB).

Two types of surgical techniques are available: tissue grafts and cellular grafts, within between autologous cultured epithelial grafts.

Microneedling is a method of transdermal drug delivery using a microneedling device applied to the skin for creating transport pathways through the stratum corneum, increasing the absorption of drugs and decreasing the duration of therapy. In addition, microneedling keeps the epidermis partially intact, fastens recovery, and limits the risk of infection and scarring. 5-Fluorouracil (5-FU) is a chemotherapeutic agent used in the treatment of many malignant tumors and it has been approved for topical use in the treatment of several dermatologic disorders. Localized hyperpigmentation occurred as a side effect of 5-FU use in cancer treatment attracts the attention toward its application in inducing repigmentation in vitiligo patches.

Latanoprost (LT), a prostaglandin F2 alpha analogue used in the treatment of glaucoma, was found to induce skin pigmentation in guinea pigs in addition to its known periocular and iridal pigmentation side effect.

Eligibility Criteria:
Inclusion Criteria:

* Patients of both sexes with stable localized vitiligo : patches should not have any increase or decrease in size or pigmentation for at least 3 months.

Exclusion Criteria:

* Pregnant or lactating female.
* Active Koebner's phenomenon.
* Age less than 10 years.
* All patients included had not received any local or systemic medication for at least 2 months before the study.
* Keloidal tendency.
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.

In order to optimize HBsAg clearance in CHB patients with low level HBsAg, the investigators enrolled patients who had received, and responded to, NAs for more than 12 months(see the inclusion criteria), and patients are switched to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks and follow up for 24 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. CHB patients who had received NAs for more than 12 months.
2. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive.
3. Hepatitis B surface antigen (HBsAg) positive and \<1500 IU/mL.
4. Hepatitis B virus DNA not detectable(Roche Cobas).

Exclusion Criteria:

1. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.
2. Patients with other factors causing liver diseases.
3. Pregnant and lactating women.
4. Patients with concomitant HIV infection or congenital immune deficiency diseases.
5. Patients with diabetes, autoimmune diseases.
6. Patients with important organ dysfunctions.
7. Patients with serious complications (e.g., infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding.)
8. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.
9. Patients who can't come back to clinic for follow-up on schedule.
Effect of Gualou Xiebai Banxia Decoction With Danshen Decoction in Treating Unstable Angina.

This study evaluates the clinical efficacy of Gualou Xiebai Banxia Decoction compounded with Danshen Decoction in the treatment of unstable angina pectoris. All of the patients will be divided into 2 arms randomly. One of the arms will be treated by conventional western medicine, the other one will be treated by Gualou Xiebai Banxia Decoction compounded with Danshen Decoction at the base of conventional western medicine.

Gualou Xiebai Banxia Decoction compounded with Danshen Decoction has the effect of promoting blood circulation and resolving phlegm, so it will be used for patients taht belong to phlegm and blood stasis type.

Eligibility Criteria:
Inclusion Criteria:

* Participants diagnosed with coronary heart disease through coronary angiography or coronary CTA;

Patients have at least one of these symptoms:

1. The stability of the nature of angina pectoris changes, that is, frequent attacks of angina pectoris, serious degree and prolonged duration;
2. Angina pectoris during rest;
3. The recent occurrence of angina pectoris caused by mild physical activity in the last month.

Exclusion Criteria:

* Patients diagnosed with stable angina; Patients with acute myocardial infarction; Chest pain caused by congenital heart disease, valvular heart disease, severe neurosis or arrhythmia; The heart function grade is III or IV; Patients with acute cerebral infarction; Patients complicated with other serious primary diseases; Patients with acute infection in recent 2 weeks; Uncontrolled hypertension (the resting blood pressure \>160/95mmHg within one week); Diabetics emerged with serious diabetic complications; Patients can't finish the questionnaire due to abnormal mental and nervous or mental disorders; Pregnant or lactating women.
Clinical Presentation of Melioidosis in Head and Neck Region

Melioidosis in head and neck was observed including clinical presentation, diagnosis with titer, and result of treatment.

This research is retrospective study about five years ( Jan 2011- Oct 2016).

Eligibility Criteria:
Inclusion Criteria:

* Patients who has the pus culture from head and neck region positive with Burkholderia pseudomallei

Exclusion Criteria:

* No
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

This is an open-label, multicentre study evaluating the effect, safety and tolerability of the two regioisomers 1-(nitrosooxy)propan-2-ol and 2-(nitrosooxy)propan-1-ol (PDNO) infusion given to COVID-19 patients with acute pulmonary hypertension (aPH) and/or acute cor pulmonale (ACP).


Eligibility Criteria:
Inclusion Criteria:

* Ability to understand and willing to sign an ICF
* Male and female patients at least 18 years of age
* Diagnosed with COVID-19 at admission to the ICU
* Diagnosed with echocardiographic signs of pulmonary artery systolic pressure (PASP) \> 40 mmHg

Exclusion Criteria:

* History of chronic pulmonary hypertension (PH), as judged by the Investigator at screening
* Known New York Heart Association (NYHA) Functional Class III or IV symptoms
* Left heart failure with ejection fraction (EF) \< 35%
* Acute coronary syndrome
* Body Mass Index (BMI) \> 45 kg/m\^2
* Estimated glomerular filtration rate (eGFR) \< 30 mL/min
* MetHb \> 3%
* PCO2 \> 7
* Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN) at screening
* Haemoglobin \< 80 g/dL
* Thrombocytopenia (platelet count \< 80000/mm\^3)
* Prothrombin time International ratio (INR) \> 1.4
* Pregnancy, or a positive pregnancy test
* Ongoing daily treatment the last 3 days with non-steroidal anti-inflammatory drugs
* Known active malignancy within the past 3 years
* History of allergy/hypersensitivity to PD or ongoing allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to PDNO
* History of any other clinically significant disease or disorder
* Participation in any interventional clinical study
Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy

This pilot clinical trial studies how well head and neck maskless immobilization device works in immobilizing patients with head and neck cancers or intracranial tumors undergoing radiation therapy. Maskless immobilization device may help to prevent movement of head during radiation therapy and immobilize patients with the same accuracy and reliability as the standard thermoplastic mask routinely used for patients receiving radiation therapy.

PRIMARY OBJECTIVES:

I. To assess the setup accuracy and reproducibility of the maskless immobilization device (MID) in patients being treated for head and neck cancers or intracranial tumors who require radiation therapy

SECONDARY OBJECTIVES:

I. To assess the patient comfort and quality of life with the MID compared to the thermoplastic mask.

Eligibility Criteria:
Inclusion Criteria:

* Patients being treated for head and neck cancers who require radiation therapy or intracranial tumors, over a 2 to 7 week period of time
* Age ≥ 18 years old
* Subjects are capable of giving informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf
* Provide signed and dated informed consent form

Exclusion Criteria

* History of prior trauma or orthopedic surgery to the cervical vertebral column/spine, which may interfere with the RT planning process
* Patient requires a neck brace for medical reasons
* Skull or bony defect in the area contacting the immobilization straps
* RT delivered by clinical setup only (no CT simulation)
Clinician-Patient Communication in Lung Cancer Care

The purpose of this study is to better understand communication between patients with lung cancer and their clinicians. The investigators are also interested in patient's perceptions of the quality of communication with his/her clinician and how these perceptions may impact patient outcomes. The clinician participating in this study and has given us permission to approach his/her eligible patients for study participation.


Eligibility Criteria:
Inclusion Criteria:

* Patients with confirmed lung cancer diagnosis or mass suspicious of lung cancer as per clinician report and/or EMR
* Lung cancer diagnosis or suspicious mass as per clinician report/EMR within 0-6 months of consent or within no more than three visits to participating clinician
* Participating clinician approves his/her patient's participation in this study per clinician report.
* Former (at least 100 cigarettes in lifetime and quit more than 30 days prior to enrollment) or current smoker (lifetime smoker who reports cigarette smoking within the past 30 days) as per self report or EMR;
* English fluency (determined through EMR or clinician report), as we do not have the resources to translate the consultations from other languages or the surveys to other languages;
* Patients must be 18 years old or older

Clinician Inclusion Criteria:

* An MSK attending physician (radiologists, medical oncologists, and surgeons), Nurse Practitioner (NP), Physician Assistant (PA), Fellow, Resident or Clinical Nurse Specialist (CNS) or Clinical Nurse (RN) who is a member of the Thoracic Disease Management Team or Pulmonary Service currently treating thoracic patients at MSK as per self report
* Clinical has individual clinic consultations to discuss adult health assessment and/or smoking history with the target patient population: English-speaking, at least 18 years of age, has a suspicious lung mass or confirmed diagnosis, is a former/current smoker, has had no more than 3 visits with clinician or had diagnosis in past 6 months as per self-report.

Exclusion Criteria:

Clinician Exclusion Criteria

* N/A
Attentional Focus Influence During Cranio-Cervical Flexion Test

The purpose of this study is to termine if a different attentional focus would alter the motor control in cervical muscles during the cranio-cervical test.

Asymptomatic subjects will be recruited to this study. Superficial electromyography of the Sternocleidomastoid, Range of Motion (ROM) and Cranio-Cervical Flexion Test (CCFT) will be measured before, immediately after change in focus of attention, 2 days after training under a particular focus of attention, and 7 days after training the task under the same focus of attention.

Subjects will be randomized into three groups: Internal focus of attention, external focus of attention and control group.

Eligibility Criteria:
Inclusion Criteria:

* Asymptomatic subjects

Exclusion Criteria:

* Cervical pain
* Historic of trauma/surgery to the cervical or thoracic spine or upper limbs
* Temporomandibular pain
* Neurological or systemic disorder
Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

606 participants with Clostridium Difficile Associated Diarrhea (CDAD) participated in this study and received either oral vancomycin or CB-183,315 (surotomycin) in a blinded fashion. Treatment lasted for 10 days and participants were followed up for at least 40 days and a maximum of 100 days. The purpose of this study was to evaluate how well surotomycin treats CDAD as compared to vancomycin.


Eligibility Criteria:
To be included in this study, participants must:

* Sign a consent form;
* Be \>= 18 and \< 90 years of age;
* Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device;
* Test positive for Clostridium difficile;
* If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study.

Participants will not be allowed into the study if they:

* Have toxic megacolon and/or known small bowel ileus;
* Have received treatment with intravenous immune globulin (IVIG) within the past 30 days;
* Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study;
* Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working;
* Have received an investigational vaccine against C. difficile;
* Have received an investigational product containing monoclonal antibodies against toxin A or B within 180 days;
* Had more than 2 episodes of CDAD within 90 days;
* Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not include appendectomy or cholecystectomy);
* Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis;
* Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study;
* Are unable to discontinue opiate treatment unless on a stable dose;
* Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter;
* Had stool studies positive for pathogenic ova and/or parasites;
* Have an intolerance or hypersensitivity to daptomycin and/or vancomycin;
* Have life-threatening illness at the time of enrollment;
* Have poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll;
* Have received an investigational drug or participated in any experimental procedure within 1 month;
* Have human immunodeficiency virus (HIV), a cluster of differentiation 4 (CD4) \< 200 cells/mm3 within 6 months of start of study therapy;
* Anticipate that certain antibacterial therapy for a non-CDAD infection will be required for \> 7 days;
* Are unable to discontinue Saccharomyces or similar probiotic;
* Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy;
* Are unable to comply with the protocol requirements;
* Have any condition that, in the opinion of the Investigator, might interfere;
* Are not expected to live for less than 8 weeks.